 Another approach to DPR proposed by Danzon et al. (2013) , called "value-based differential pricing", would be to have prices reflecting marginal value acknowledged in each country through the use of individual incremental cost-effectiveness ratio (ICER) threshold based on willingness to pay within each country [5] .
 Other approaches involve separating price setting and the recovery of fixed R&D costs following different options [4] .
DPR in debate
• DPR is highly discussed among national, EU institutions and industry, as illustrated in Table 1, given the differences in GDP per capita and price levels of EU countries (Figures 1&2).
CONCLUSIONS
• DPR is already in place in EU countries, however current DPR does not aim to enhance access to innovative pharmaceuticals in small low income countries but to acknowledge negotiation power of large high income markets.
• Implementation of proactive DPR schemes within EU is complex:
1. To overcome resistance from high income markets. 2. To overcome technical issues to implement an optimised DPR system.  Wide coordination and interaction, between the countries and the industry to minimize various counteracting policies and initiatives will be required.
• In depth research is needed to assess how both ERP and DPR systems might possibly interact to maximize cost savings for public healthcare systems through ERP, while maximizing patient access to drugs through DPR.  Current price differential is more a result of pricing strategies, negotiations and price cuts rather than DPR system implementation [4, 14] .
• Several challenges were reported to limit DPR implementation within the EU among which are: [1, 4, 13, 14] 1. DPR scheme is based on average per capita income.
 It might question the price affordability of drugs when countries with similar per capita income may have a large imbalance in the distribution of income across the population.
2. Manufacturers attempt to apply higher price in low income markets because of the low sales volume and lower price in high income markets because of high sales volume. 3. Differential distribution margins. 4. Risk of parallel trade. 5. Use of ERP where prices and undisclosed rebates in high income countries drive high prices in lower income countries.
 Various confidential market access agreements between public payers and manufacturers made EU prices non transparent leading to difficulty to compare prices.
Institutions Date Key statement
The High level Pharmaceutical forum
2008 "A similar price-level leads to a different level of affordability depending on the economic situation of each Member State. Attention could be given to measures that allow companies to offer medicines at affordable price in each EU market." [8] Belgian Presidency of the Council of the European Union 2010 "Ideally, valuable innovative drugs should be launched in all markets and available at an affordable price. It should be perhaps explored whether a system of price differential can be applied in function of GDP per capita to enable such access." [9] Steering group on access to medicines in Europe (Project Group on facilitating supply in small markets)
2013 "The concept of differential pricing of medicinal products needs further scrutiny in general as well as in the specific terms of small markets." [10] EURORDIS 2014 "Alongside the policy debate, pilots may be pursued by individual companies adopting DPR approach to the price of medicinal products, incorporating a deal on price/volume." [11] EFPIA 2014 "Member State action and support from the EU are required to create a framework to enable and encourage voluntary recourse to differentiated pricing." [12] DISCUSSION • Development of DPR schemes will need to take into considerations:
 3 key features: DPR formula, approaches to set DPR, and DPR implementation processes (Table 2) ; optimised scheme will have to consider these features individually and in combination to be able to achieve a clear, reproducible, simple to implement, and effective price differentiation.  Coordination of different schemes: this will be required to achieve price control and savings through ERP and wider access through DPR while recognizing the value of medicines.  Integrating HTA in price setting through a coordinated DPR/ERP scheme: this will be a challenge as such schemes are likely to conduct to a price setting before HTA. Shall a price be set at EU level through a formula it remains essential that the HTA process is integrated in the pricing sequence at one point or another. This will be a true challenge as HTA bodies at EU level do have very different timelines.
Examples of variables for DPR Formula
Examples of approaches to set DPR Examples of DPR implementation processes
• Affordability: e.g. GDP, power purchase parity • Market size: potential volume of purchase such as population size, disease prevalence • Disease characteristics: e.g. disease burden, life expectancy, DALY • Demand elasticity: could be approximated by health care as well as pharmaceuticals spending per capita and proportion of GDP per capita invested in health care and pharmaceuticals
• Lower price approach: e.g. covering the marginal cost of producing and distributing a given product • Higher price approach: might be more complex to achieve. Solution might be to wait for initial high prices are set • VBP approach: price is set based on ICER and there are different threshold in different countries or different tiered according to a formula to be defined ICER is a complex information and formula may have to introduce cost of services as well as clinical practices. This may render the differential valuebased pricing very difficult to implement in practice
• Country specific transparent price: In that case, distribution cost will not be inflated but this may open an avenue to parallel trade • Country specific confidential price: In that case, the distribution cost is inflated as the listed price does not reflect the net price paid by the payers • Countries with similar characteristics clustered and price differentiated by cluster (price may be transparent or confidential) • Risk-sharing agreements might also achieve price differential • DPR may apply to specific product categories:
e.g. all products or restricted to specific products 
